MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a
biopharmaceutical company focused on the discovery and development
of innovative medicines targeting microRNAs, today announced
continued technical and clinical collaboration following release of
Regulus' positive topline results from the second cohort of
patients in its Phase 1b MAD
(multiple ascending dose) study of RGLS8429 for the treatment of
Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two
companies began the collaboration in 2020 to support Regulus'
biomarker analysis for the clinical development of anti-miR-17
therapies for ADPKD treatment.
To generate the recently reported topline clinical data for
RGLS8429, Regulus utilized Bio-Techne's Simple WesternTM
platforms and its ExosomeDx CLIA laboratory. Simple Western
enables full automation of western blotting for efficient and
streamlined workflows to quantify expression and determine size and
identity of therapeutic proteins. ExosomeDx, a Bio-Techne brand, is
a world leader in developing liquid biopsy-based diagnostics with
products and technologies for the isolation and analysis of
exosomes to measure RNA, cell-free DNA, and proteins.
Regulus developed high-performance biomarker assays to measure
polycystin 1 (PC1) and polycystin 2 (PC2) levels in urine samples
using the fully automated Simple Western platform, which provides
sensitive and quantitative protein expression readouts using a few
microliters of a patient sample. Measuring PC1 and PC2 levels
provides key mechanistic and pharmacodynamic information because
patients with ADPKD have been reported to have low levels of these
two proteins. The testing is being performed at Bio-Techne's
ExosomeDx CLIA laboratory, to take advantage of their exosome
expertise and clinical testing capabilities.
"Congratulations to the Regulus team for
achieving this important milestone and advancing this study in
patients living with ADPKD," said Will
Geist, Bio-Techne's President, Protein Sciences Segment. "We
look forward to continuing to work with Regulus on the next phase
of the study and enabling other biotech companies to develop and
advance cutting-edge therapeutics that improve global
healthcare."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated over $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit http://www.bio-techne.com or follow the
Company on social media at Facebook, LinkedIn, Twitter or
YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About Regulus
Regulus Therapeutics Inc. is a biopharmaceutical company focused
on the discovery and development of innovative medicines targeting
microRNAs. Regulus has leveraged its oligonucleotide drug discovery
and development expertise to develop a pipeline complemented by a
rich intellectual property estate in the microRNA field. Regulus
maintains its corporate headquarters in San Diego, CA.
Regulus Contact
Investor Relations Contact:
Cris Calsada
Chief Financial Officer
858-202-6376
ccalsada@regulusrx.com
Media Contact:
Sarah Sutton
Argot Partners
212-600-1902
regulus@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-highlights-recently-announced-top-line-biomarker-data-from-partner-regulus-therapeutics-using-the-companys-proprietary-technology-302152199.html
SOURCE Bio-Techne Corporation